1-15 of 15
Keywords: Topotecan
Close
Sort by
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2011) 80 (5-6): 390–394.
Published Online: 05 August 2011
...D. Lorusso; S. Mainenti; A. Pietragalla; E. Fusco; P. Malaguti; V. Masciullo; G. Scambia Objective: It was the aim of our study to evaluate the efficacy and safety of weekly topotecan in patients with advanced or recurrent cervical disease. Methods: Topotecan was administered intravenously...
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2005) 69 (2): 154–158.
Published Online: 21 September 2005
... in response to topotecan as second-line therapy. Methods: Twenty-eight patients with advanced ovarian carcinoma, pretreated with standard platinum/paclitaxel chemotherapy, received topotecan as single-agent second-line therapy. Tumors were investigated by molecular analysis for p53 mutations in tumor samples...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2005) 68 (4-6): 293–298.
Published Online: 17 August 2005
... following platinum-based therapy, other agents such as paclitaxel, pegylated liposomal doxorubicin, topotecan or gemcitabine should be used. If the tumor recurs after 6 months, a combination therapy of platinum and paclitaxel has proven to be the most effective. Reasonable options in progressive disease...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2001) 61 (4): 265–270.
Published Online: 21 November 2001
...S. Kakolyris; Ch. Kouroussis; J. Souglakos; D. Mavroudis; S. Agelaki; K. Kalbakis; N. Androulakis; N. Vardakis; L. Vamvakas; V. Georgoulias Objectives: Topotecan, a potent inhibitor of the enzyme topoisomerase I, has shown an interesting activity against several types of solid tumors, most notably...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2001) 61 (Suppl. 1): 55–59.
Published Online: 26 September 2001
...Joan H. Schiller Topotecan (HYCAMTIN ® ; GlaxoSmithKline, Brentford, Middlesex, UK) is a novel topoisomerase I inhibitor with potentially broad applicability in the treatment of solid and hematologic malignancies. In addition to its use in relapsed small-cell lung cancer (SCLC), topotecan is under...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2001) 61 (Suppl. 1): 47–54.
Published Online: 26 September 2001
...J.L. Pujol; J. von Pawel; S. Tumolo; A. Martoni; S. Hearn; S.Z. Fields; G. Ross Topotecan is a topoisomerase I inhibitor and an analogue of camptothecin with demonstrated activity in small-cell lung cancer. However, less is known about the potential role of topotecan in advanced non-small-cell lung...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2001) 61 (Suppl. 1): 30–34.
Published Online: 26 September 2001
..., coupled with suboptimal activity of single-agent therapy, have prompted the investigation of multidrug regimens in the treatment of NSCLC. One potential combination regimen, in which each agent has antitumor activity in NSCLC monotherapy, is topotecan plus paclitaxel. This article will review...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2001) 61 (Suppl. 1): 3–13.
Published Online: 26 September 2001
... survival is mounting for various combinations of established regimens (e.g., PE) with newer drugs exhibiting novel mechanisms of action and single-agent antitumor activity, such as gemcitabine, paclitaxel, docetaxel, vinorelbine, and topotecan. This article reviews the current standards of care in SCLC...
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2001) 61 (Suppl. 1): 42–46.
Published Online: 26 September 2001
...John R. Eckardt The single-agent activity of intravenous (i.v.) topotecan has been established in small-cell lung cancer (SCLC), with overall tumor responses of 39% in previously untreated patients and 11–37% in relapsed patients. An oral formulation of topotecan has been developed that is more...
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2001) 61 (Suppl. 1): 14–24.
Published Online: 26 September 2001
... the taxanes, mitotic spindle inhibitors, antimetabolites, and topoisomerase I and II inhibitors. The molecular target of several of these new agents is topoisomerase I, an enzyme that is essential for DNA replication and is up-regulated in tumor cells. Inhibition of this enzyme by drugs such as topotecan...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2000) 60 (1): 19–23.
Published Online: 28 December 2000
...Stefano Greggi; M. Giovanna Salerno; Giuseppe D’Agostino; Gabriella Ferrandina; Domenica Lorusso; Luigi Manzione; Salvatore Mancuso; Giovanni Scambia 24 patients were enrolled into a phase I–II study conducted to determine the maximum tolerated doses of topotecan-gemcitabine in sequential...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1999) 56 (1): 1–12.
Published Online: 18 January 1999
...C. Kollmannsberger; K. Mross; A. Jakob; L. Kanz; C. Bokemeyer Topotecan, a water-soluble analogue of camptothecin, is a newly available cytotoxic agent which acts as an inhibitor of topoisomerase I, an enzyme necessary for DNA replication. Topotecan is a semisynthetic product derived from...